Improved Response by Co-targeting EGFR/EGFRvIII and Src Family Kinases in Human Cancer Cells

REFERENCES

• Zandi R., Larsen A. B., Andersen P., Stockhausen M. T., Poulsen H. S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013–2023
   PubMed Web of Science ®Google Scholar
• Summy J. M., Gallick G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337–358
   PubMed Web of Science ®Google Scholar
• Zhu S., Bjorge J. D., Fujita D. J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 2007; 67: 10129–10137
   PubMed Web of Science ®Google Scholar
• Hara F., Aoe M., Doihara H., Taira N., Shien T., Takahashi H., et al. Antitumor effect of gefitinib (‘Iressa’) on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005; 226: 37–47
   PubMed Web of Science ®Google Scholar
• Small E. J., Fontana J., Tannir N., DiPaola R. S., Wilding G., Rubin M., et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007; 100: 765–769
   PubMed Web of Science ®Google Scholar
• Posadas E. M., Liel M. S., Kwitkowski V., Minasian L., Godwin A. K., Hussain M. M., et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109: 1323–1330
   PubMed Web of Science ®Google Scholar
• Stommel J. M., Kimmelman A. C., Ying H., Nabioullin R., Ponugoti A. H., Wiedemeyer R., et al. Co-activation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287–290
   PubMed Web of Science ®Google Scholar
• Engelman J. A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J. O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043
   PubMed Web of Science ®Google Scholar
• Hiscox S., Morgan L., Green T. P., Barrow D., Gee J., Nicholson R. I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006; 97: 263–274
   PubMedGoogle Scholar
• Ishizawar R., Parsons S. J. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209–214
   PubMed Web of Science ®Google Scholar
• Bromann P. A., Korkaya H., Courtneidge S. A. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23: 7957–7968
   PubMed Web of Science ®Google Scholar
• Pedersen M. W., Pedersen N., Damstrup L., Villingshøj M., Sønder S. U., Rieneck K., et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation. J Cell Biochem 2005; 96: 412–427
   PubMed Web of Science ®Google Scholar
• Learn C. A., Hartzell T. L., Wikstrand C. J., Archer G. E., Rich J. N., Friedman A. H., et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004; 10: 3216–3224
   PubMed Web of Science ®Google Scholar
• Pedersen M. W., Pedersen N., Ottesen L. H., Poulsen H. S. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 2005; 93: 915–923
   PubMed Web of Science ®Google Scholar
• Kwok T. T., Sutherland R. M. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 1991; 64: 251–254
   PubMed Web of Science ®Google Scholar
• Andersen P., Pedersen M. W., Woetmann A., Villingshoj M., Stockhausen M. T., Odum N., et al. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 2007; 122: 342–349
   Web of Science ®Google Scholar
• Kamer A. R., Sacks P. G., Vladutiu A., Liebow C. EGF mediates multiple signals: dependence on the conditions. Int J Mol Med 2004; 13: 143–147
   PubMed Web of Science ®Google Scholar
• Larsen A. B., Pedersen M. W., Stockhausen M. T., Grandal M. V., van Deurs B., Poulsen H. S. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007; 5: 283–293
   PubMedGoogle Scholar
• Pedersen M. W., Tkach V., Pedersen N., Berezin V., Poulsen H. S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004; 108: 643–653
   PubMed Web of Science ®Google Scholar
• Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593–602
   PubMed Web of Science ®Google Scholar
• Montgomery R. B. Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int J Cancer 2002; 101: 111–117
   PubMed Web of Science ®Google Scholar
• Sakamoto M., Takamura M., Ino Y., Miura A., Genda T., Hirohashi S. Involvement of c-Src in carcinoma cell motility and metastasis. Jpn J Cancer Res 2001; 92: 941–946
   PubMedGoogle Scholar